Liu Yan, He Enping, Zhang Yanling, Liu Yitong, Wang Yingshuang, Chen Siyu, Wu Xinyu, Zeng Youqing, Leng Ping
Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
The Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital), Chengdu, China.
Gland Surg. 2022 Dec;11(12):1984-2002. doi: 10.21037/gs-22-716.
WW domain binding protein 2 (), considered an emerging breast cancer gene, functions as a binding partner for WW domain proteins. The gene is involved in mediating the malignant development and clinical drug resistance of breast cancer, but its potential mechanism remains unclear. Therefore, it is necessary to elucidate the mechanism of WBP2 in breast cancer, which will help to provide new methods for clinical diagnosis and treatment of breast cancer.
The PubMed database was searched using the terms "WW Domain Binding Protein 2" or "WBP2", "breast cancer" or "breast neoplasms" or "human cancer" from January 1997 through August 2022. Through the screening and evaluation of titles and abstracts, about 120 English articles were included in this study.
By describing the multiple regulatory functions of at the transcriptional, post-transcriptional, and post-translational levels, and summarizing how WBP2 as a key node crosstalks multiple signaling pathways, we reveal the ability of WBP2 to promote breast cancer malignant progression. In different subtypes of breast cancer, the mechanism of WBP2-mediated drug resistance is related to estrogen receptor and epidermal growth factor receptor (EGFR) 2 status, and hormones may be an essential factor in WBP2-mediated drug resistance. In addition, we discuss the application prospects of WBP2 in targeted therapy and immunotherapy and propose therapeutic strategies to overcome drug resistance in breast cancer by jointly targeting WBP2 and its related molecules. This provides a theoretical basis for the innovation of breast cancer targeted drugs.
WBP2 is a promising target for breast cancer therapy. Nuclear WBP2, as the main functional form of WBP2 after its activation, is a meaningful indicator for the diagnosis and prediction of breast cancer progression.
WW结构域结合蛋白2（WBP2）被认为是一种新兴的乳腺癌相关基因，可作为WW结构域蛋白的结合伴侣发挥作用。WBP2基因参与介导乳腺癌的恶性发展和临床耐药性，但其潜在机制尚不清楚。因此，有必要阐明WBP2在乳腺癌中的作用机制，这将有助于为乳腺癌的临床诊断和治疗提供新方法。
使用“WW结构域结合蛋白2”或“WBP2”、“乳腺癌”或“乳腺肿瘤”或“人类癌症”等关键词，在1997年1月至2022年8月期间检索PubMed数据库。通过对标题和摘要的筛选和评估，本研究纳入了约120篇英文文章。
通过描述WBP2在转录、转录后和翻译后水平的多种调控功能，并总结WBP2作为关键节点如何与多种信号通路相互作用，我们揭示了WBP2促进乳腺癌恶性进展的能力。在不同亚型的乳腺癌中，WBP2介导的耐药机制与雌激素受体和表皮生长因子受体（EGFR）2的状态有关，激素可能是WBP2介导耐药的重要因素。此外，我们讨论了WBP2在靶向治疗和免疫治疗中的应用前景，并提出了通过联合靶向WBP2及其相关分子来克服乳腺癌耐药性的治疗策略。这为乳腺癌靶向药物的创新提供了理论依据。
WBP2是一种有前景的乳腺癌治疗靶点。核WBP2作为WBP2激活后的主要功能形式，是乳腺癌进展诊断和预测的有意义指标。
